Biocon receives EIR from USFDA for good manufacturing practice inspection
Biocon on
Friday said it has received the establishment inspection report (EIR) from US health
regulator for the post-approval and good manufacturing practice (GMP)
inspection of its small molecules manufacturing facility in Bengaluru.
"The
EIR has been closed with a voluntary action indicated (VAI) classification for
the observations, the company spokesperson said in a filing to BSE.
"Biocon has received
the EIR from the US Food and Drug
Administration (FDA) for the post-approval and GMP inspection
of its small molecules active pharmaceutical ingredient (API) manufacturing
facility at 20th KM, Biocon Campus,
Bengaluru, conducted between Feb 20 and Feb 26, 2020," as per the filing.
Comments
Post a Comment